IRB #

STUDY00022082

Title

A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors

Principal Investigator

Shivaani Kummar

Study Purpose

The purpose of this study is to find out if the investigational drug called ADCT-301 is safe in people with advanced cancers and what effects it has on that cancer.

Medical Condition(s)

Advanced cancers

Eligibility Criteria

Male and Female participants of 18 years of age and older.
Diagnosed with advanced or metastatic cancer

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

How long you participate in this study depends on side effects you may have to the study drug. It also depends on how your cancer might respond to the study drug.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
trials@ohsu.edu

Sponsor

ADC Therapeutics

Recruitment End

10/01/2022

Compensation Provided

No


Go Back